Endocrine and Metabolic Disease Research Center, School of Medicine, University of Zulia, Maracaibo, Venezuela.
Departamento de Endocrinología y Nutrición. Hospital General Universitario Gregorio Marañón, Madrid, España.
Curr Cardiol Rev. 2023;19(4):e020223213408. doi: 10.2174/1573403X19666230202164524.
Atherosclerosis is one of the most relevant and prevalent cardiovascular diseases of our time. It is one of the pathological entities that increases the morbidity and mortality index in the adult population. Pathophysiological connections have been observed between atherosclerosis and the gut microbiome (GM), represented by a group of microorganisms that are present in the gut. These microorganisms are vital for metabolic homeostasis in humans. Recently, direct and indirect mechanisms through which GM can affect the development of atherosclerosis have been studied. This has led to research into the possible modulation of GM and metabolites as a new target in the prevention and treatment of atherosclerosis. The goal of this review is to analyze the physiopathological mechanisms linking GM and atherosclerosis that have been described so far. We also aim to summarize the recent studies that propose GM as a potential target in atherosclerosis management.
动脉粥样硬化是我们这个时代最重要和最普遍的心血管疾病之一。它是增加成年人群发病率和死亡率指数的病理实体之一。在动脉粥样硬化和肠道微生物组(GM)之间已经观察到病理生理学联系,GM 是存在于肠道中的一组微生物。这些微生物对人类的代谢稳态至关重要。最近,已经研究了 GM 通过直接和间接机制影响动脉粥样硬化发展的方式。这导致了对 GM 和代谢物作为动脉粥样硬化预防和治疗新靶点的可能调节的研究。本综述的目的是分析迄今为止描述的将 GM 与动脉粥样硬化联系起来的生理病理机制。我们还旨在总结提出 GM 作为动脉粥样硬化管理潜在靶点的最新研究。